Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge

被引:16
|
作者
Sun, Jialei [1 ]
Ennis, Jane [2 ]
Turner, Jeffrey D. [2 ]
Chu, Justin Jang Hann [1 ]
机构
[1] Natl Univ Singapore, Lab Mol RNA Virol & Antiviral Strategies, Dept Microbiol & Immunol, Yong Loo Lin Sch Med,Natl Univ Hlth Syst, MD4 Level 5,5 Sci Dr 2, Singapore 117597, Singapore
[2] Defyrus Inc, 2 Bloor St West,Suite 2602, Toronto, ON M4W 3E2, Canada
关键词
DEF201; EV71; Murine model; Prophylactic effects; Therapeutic effects; VIRUS; ENCEPHALITIS; ACTIVATION;
D O I
10.1016/j.antiviral.2016.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Enterovirus 71 (EV71) causes hand-foot-and-mouth diseases as well as neurological complications in young children. Interferon (IFN) can inhibit the replication of many viruses with low cytotoxic effects. Previously, an adenovirus vectored mouse interferon-a (DEF201), subtype 5, was generated by Wu et al, 2007. In this study, the antiviral effects of DEF201 against EV71 were evaluated in a murine model. 6-day-old BALB/c mice were administered a single dose of DEF201 before or after infection with lethal dose of EV71. The survival rate, clinical symptoms, tissue viral loads and histology pathogenesis were evaluated. IFN gene expression following a single dose of DEF201 maintained high concentrations of 100 -9000 pg/mL for more than 7 days in mice serum. Pre-infection administration of a single dose of 10(6) PFU of DEF201 offered full protection of the mice against EV71 infection compared with the empty Ad5 vector control. In addition, virus load in DEF201-treated mice muscle tissue was significantly decreased as compared with empty vector control. Histopathology analysis revealed that DEF201 significantly prevented the development of severe tissue damage with reduction of viral antigen in the murine muscle tissue. Post-infection treatment at 6 h offered full protection and partial protection at 12 h, indicating that DEF201 could be used as an anti-EV71 therapeutic agent in early stage of EV71 infection. In addition, our study showed that DEF201 enhanced the neutralization ability of serum in EV71-vaccinated mice, implying that DEF201 could promote the production of specific anti-EV71 antibodies. In conclusion, single dose of DEF201 is highly efficacious as a prophylactic agent against EV71 infection in vivo. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 42 条
  • [1] Single-dose Intranasal Delivery with DEF201 (Adenovirus Vectored Mouse Interferon-α) Protects Against Phlebovirus and Sars Coronavirus Challenge
    Gowen, Brian
    Barnard, Dale
    Wong, Min-Hui
    Larson, Deanna
    Wu, Josh
    Ennis, Jane
    Morrey, John
    Turner, Jeffery
    ANTIVIRAL RESEARCH, 2010, 86 (01) : A34 - A34
  • [2] Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model
    Junliang Chang
    Jingliang Li
    Wei Wei
    Xin Liu
    Guanchen Liu
    Jiaxin Yang
    Wenyan Zhang
    Xiao-Fang Yu
    Immunologic Research, 2015, 62 : 306 - 315
  • [3] Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model
    Chang, Junliang
    Li, Jingliang
    Wei, Wei
    Liu, Xin
    Liu, Guanchen
    Yang, Jiaxin
    Zhang, Wenyan
    Yu, Xiao-Fang
    IMMUNOLOGIC RESEARCH, 2015, 62 (03) : 306 - 315
  • [4] Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection
    Chen, Huixin
    Min, Nyo
    Ma, Luyao
    Mok, Chee-Keng
    Chu, Justin Jang Hann
    PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (12): : e0008910
  • [5] A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease
    Campos, Rafael Kroon
    Preciado-Llanes, Lorena
    Azar, Sasha R.
    Lopez-Camacho, Cesar
    Reyes-Sandoval, Arturo
    Rossi, Shannan L.
    PATHOGENS, 2019, 8 (04):
  • [6] A Single Sublingual Dose of an Adenovirus-Based Vaccine Protects against Lethal Ebola Challenge in Mice and Guinea Pigs
    Choi, Jin Huk
    Schafer, Stephen C.
    Zhang, Lihong
    Kobinger, Gary P.
    Juelich, Terry
    Freiberg, Alexander N.
    Croyle, Maria A.
    MOLECULAR PHARMACEUTICS, 2012, 9 (01) : 156 - 167
  • [7] Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice
    Sun, Shiyang
    Gao, Fan
    Mao, Qunying
    Shao, Jie
    Jiang, Liping
    Liu, Dawei
    Wang, Yiping
    Yao, Xin
    Wu, Xing
    Sun, Bo
    Zhao, Dandan
    Ma, Youlei
    Lu, Jingcai
    Kong, Wei
    Jiang, Chunlai
    Liang, Zhenglun
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (10) : 2406 - 2413
  • [8] A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge
    Lin, Yu-Li
    Cheng, Pei-Yun
    Chin, Chiao-Li
    Chuang, Kuan-Ting
    Lin, Jing-Yi
    Chang, Ning
    Pan, Chun-Kei
    Lin, Cheng-Sheng
    Pan, Siao-Cian
    Chiang, Bor-Luen
    JOURNAL OF BIOMEDICAL SCIENCE, 2023, 30 (01)
  • [9] A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge
    Yu-Li Lin
    Pei-Yun Cheng
    Chiao-Li Chin
    Kuan-Ting Chuang
    Jing-Yi Lin
    Ning Chang
    Chun-Kei Pan
    Cheng-Sheng Lin
    Siao-Cian Pan
    Bor-Luen Chiang
    Journal of Biomedical Science, 30
  • [10] Single-Dose Intranasal Treatment with DEF201 (Adenovirus Vectored Consensus Interferon) Prevents Lethal Disease Due to Rift Valley Fever Virus Challenge
    Gowen, Brian B.
    Ennis, Jane
    Bailey, Kevin W.
    Vest, Zachary
    Scharton, Dionna
    Sefing, Eric J.
    Turner, Jeffrey D.
    VIRUSES-BASEL, 2014, 6 (03): : 1410 - 1423